vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Forestar Group Inc.（FOR）财务数据对比。点击上方公司名可切换其他公司
Forestar Group Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.5倍（$273.0M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 5.6%，领先7.7%），Forestar Group Inc.同比增速更快（9.0% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $-157.1M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -9.6%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
AMPH vs FOR — 直观对比
营收规模更大
FOR
是对方的1.5倍
$183.1M
营收增速更快
FOR
高出10.9%
-1.8%
净利率更高
AMPH
高出7.7%
5.6%
自由现金流更多
AMPH
多$181.7M
$-157.1M
两年增速更快
AMPH
近两年复合增速
-9.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $273.0M |
| 净利润 | $24.4M | $15.4M |
| 毛利率 | 46.8% | 20.1% |
| 营业利润率 | 19.4% | 7.6% |
| 净利率 | 13.3% | 5.6% |
| 营收同比 | -1.8% | 9.0% |
| 净利润同比 | -35.7% | -6.7% |
| 每股收益（稀释后） | $0.51 | $0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHFOR
| Q4 25 | $183.1M | $273.0M | ||
| Q3 25 | $191.8M | $670.5M | ||
| Q2 25 | $174.4M | $390.5M | ||
| Q1 25 | $170.5M | $351.0M | ||
| Q4 24 | $186.5M | $250.4M | ||
| Q3 24 | $191.2M | $551.3M | ||
| Q2 24 | $182.4M | $318.4M | ||
| Q1 24 | $171.8M | $333.8M |
净利润AMPHFOR
| Q4 25 | $24.4M | $15.4M | ||
| Q3 25 | $17.4M | $86.9M | ||
| Q2 25 | $31.0M | $32.9M | ||
| Q1 25 | $25.3M | $31.6M | ||
| Q4 24 | $38.0M | $16.5M | ||
| Q3 24 | $40.4M | $81.5M | ||
| Q2 24 | $37.9M | $38.7M | ||
| Q1 24 | $43.2M | $45.0M |
毛利率AMPHFOR
| Q4 25 | 46.8% | 20.1% | ||
| Q3 25 | 51.4% | 22.3% | ||
| Q2 25 | 49.6% | 20.4% | ||
| Q1 25 | 50.0% | 22.6% | ||
| Q4 24 | 46.5% | 22.0% | ||
| Q3 24 | 53.3% | 23.9% | ||
| Q2 24 | 52.2% | 22.5% | ||
| Q1 24 | 52.4% | 24.9% |
营业利润率AMPHFOR
| Q4 25 | 19.4% | 7.6% | ||
| Q3 25 | 13.2% | 16.9% | ||
| Q2 25 | 24.2% | 11.2% | ||
| Q1 25 | 21.9% | 11.6% | ||
| Q4 24 | 24.2% | 8.7% | ||
| Q3 24 | 29.8% | 19.7% | ||
| Q2 24 | 30.3% | 16.2% | ||
| Q1 24 | 27.9% | 17.6% |
净利率AMPHFOR
| Q4 25 | 13.3% | 5.6% | ||
| Q3 25 | 9.0% | 13.0% | ||
| Q2 25 | 17.8% | 8.4% | ||
| Q1 25 | 14.8% | 9.0% | ||
| Q4 24 | 20.4% | 6.6% | ||
| Q3 24 | 21.1% | 14.8% | ||
| Q2 24 | 20.8% | 12.2% | ||
| Q1 24 | 25.1% | 13.5% |
每股收益（稀释后）AMPHFOR
| Q4 25 | $0.51 | $0.30 | ||
| Q3 25 | $0.37 | $1.70 | ||
| Q2 25 | $0.64 | $0.65 | ||
| Q1 25 | $0.51 | $0.62 | ||
| Q4 24 | $0.74 | $0.32 | ||
| Q3 24 | $0.78 | $1.59 | ||
| Q2 24 | $0.73 | $0.76 | ||
| Q1 24 | $0.81 | $0.89 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $211.7M |
| 总债务越低越好 | $608.7M | $793.2M |
| 股东权益账面价值 | $788.8M | $1.8B |
| 总资产 | $1.6B | $3.2B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.44× |
8季度趋势，按日历期对齐
现金及短期投资AMPHFOR
| Q4 25 | $282.8M | $211.7M | ||
| Q3 25 | $276.2M | $379.2M | ||
| Q2 25 | $231.8M | $189.2M | ||
| Q1 25 | $236.9M | $174.3M | ||
| Q4 24 | $221.6M | $132.0M | ||
| Q3 24 | $250.5M | $481.2M | ||
| Q2 24 | $217.8M | $359.2M | ||
| Q1 24 | $289.6M | $416.2M |
总债务AMPHFOR
| Q4 25 | $608.7M | $793.2M | ||
| Q3 25 | $608.6M | $802.7M | ||
| Q2 25 | $607.7M | $872.8M | ||
| Q1 25 | $603.9M | $872.5M | ||
| Q4 24 | $601.6M | $806.8M | ||
| Q3 24 | $596.4M | $706.4M | ||
| Q2 24 | $586.9M | $706.1M | ||
| Q1 24 | $594.0M | $705.7M |
股东权益AMPHFOR
| Q4 25 | $788.8M | $1.8B | ||
| Q3 25 | $776.7M | $1.8B | ||
| Q2 25 | $757.5M | $1.7B | ||
| Q1 25 | $751.3M | $1.6B | ||
| Q4 24 | $732.3M | $1.6B | ||
| Q3 24 | $727.7M | $1.6B | ||
| Q2 24 | $713.3M | $1.5B | ||
| Q1 24 | $672.4M | $1.5B |
总资产AMPHFOR
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $1.7B | $3.1B | ||
| Q2 25 | $1.6B | $3.1B | ||
| Q1 25 | $1.6B | $3.0B | ||
| Q4 24 | $1.6B | $3.0B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.5B | $2.7B | ||
| Q1 24 | $1.6B | $2.6B |
负债/权益比AMPHFOR
| Q4 25 | 0.77× | 0.44× | ||
| Q3 25 | 0.78× | 0.45× | ||
| Q2 25 | 0.80× | 0.52× | ||
| Q1 25 | 0.80× | 0.53× | ||
| Q4 24 | 0.82× | 0.50× | ||
| Q3 24 | 0.82× | 0.44× | ||
| Q2 24 | 0.82× | 0.47× | ||
| Q1 24 | 0.88× | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $-157.0M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $-157.1M |
| 自由现金流率自由现金流/营收 | 13.4% | -57.5% |
| 资本支出强度资本支出/营收 | 4.5% | 0.0% |
| 现金转化率经营现金流/净利润 | 1.35× | -10.19× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $93.0M |
8季度趋势，按日历期对齐
经营现金流AMPHFOR
| Q4 25 | $32.9M | $-157.0M | ||
| Q3 25 | $52.6M | $256.3M | ||
| Q2 25 | $35.6M | $15.8M | ||
| Q1 25 | $35.1M | $-19.8M | ||
| Q4 24 | $29.0M | $-450.0M | ||
| Q3 24 | $60.0M | $119.2M | ||
| Q2 24 | $69.1M | $-61.7M | ||
| Q1 24 | $55.3M | $-59.2M |
自由现金流AMPHFOR
| Q4 25 | $24.6M | $-157.1M | ||
| Q3 25 | $47.2M | $255.6M | ||
| Q2 25 | $25.0M | $15.0M | ||
| Q1 25 | $24.4M | $-20.5M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | $118.4M | ||
| Q2 24 | $63.1M | $-62.3M | ||
| Q1 24 | $46.5M | $-59.8M |
自由现金流率AMPHFOR
| Q4 25 | 13.4% | -57.5% | ||
| Q3 25 | 24.6% | 38.1% | ||
| Q2 25 | 14.3% | 3.8% | ||
| Q1 25 | 14.3% | -5.8% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | 21.5% | ||
| Q2 24 | 34.6% | -19.6% | ||
| Q1 24 | 27.1% | -17.9% |
资本支出强度AMPHFOR
| Q4 25 | 4.5% | 0.0% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 6.1% | 0.2% | ||
| Q1 25 | 6.3% | 0.2% | ||
| Q4 24 | 6.7% | 0.0% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.2% | ||
| Q1 24 | 5.1% | 0.2% |
现金转化率AMPHFOR
| Q4 25 | 1.35× | -10.19× | ||
| Q3 25 | 3.03× | 2.95× | ||
| Q2 25 | 1.15× | 0.48× | ||
| Q1 25 | 1.39× | -0.63× | ||
| Q4 24 | 0.76× | -27.27× | ||
| Q3 24 | 1.48× | 1.46× | ||
| Q2 24 | 1.82× | -1.59× | ||
| Q1 24 | 1.28× | -1.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
